← Back to Clinical Trials
Recruiting NCT06851091

NCT06851091 Investigation of the Relationship Between Central Sensitization and Balance in Fibromyalgia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06851091
Status Recruiting
Phase
Sponsor Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Condition Fibromyalgia Syndrome
Study Type OBSERVATIONAL
Enrollment 75 participants
Start Date 2025-02-18
Primary Completion 2025-09-04

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL
Interventions
Biodex Balance SystemPressure Pain Threshold (PPT) Measurement with AlgometerConditioned Pain Modulation (CPM)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 75 participants in total. It began in 2025-02-18 with a primary completion date of 2025-09-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the study is to investigate the relationship between central sensitization parameters and changes in static and dynamic balance in patients with fibromyalgia. The main questions it aims to answer are: * Do central sensitization parameters differ in patients with fibromyalgia compared to healthy individuals? * How is balance performance in these individuals compared to healthy controls? * Do central sensitization parameters affect static and dynamic balance in patients with fibromyalgia? * Do central sensitization parameters lead to quantitative changes in balance in patients with fibromyalgia?

Eligibility Criteria

Inclusion Criteria: * Diagnosis of FMS according to the ACR 2016 diagnostic criteria * Being between the ages of 18 and 65 * Being literate * Providing informed consent by signing the voluntary consent form Exclusion Criteria: * Being under 18 years old or over 65 years old * Presence of vestibular disorders * Having undergone spinal and/or extremity surgery (such as for back/hip/knee/foot) within the last 6 months * History of lower extremity amputation * Presence of spinal deformities * Peripheral arterial disease * Vitamin B12 deficiency * Any neurological disorder (e.g., stroke, traumatic brain injury, multiple sclerosis, Parkinson's disease, central nervous system malignancies, etc.) * Severe cardiopulmonary insufficiency (stage 3-4) * Uncontrolled systemic diseases such as hypertension and diabetes * Presence of systemic inflammatory diseases, malignancies, or active infections * Pregnancy

Contact & Investigator

Central Contact

Melike Ünsal Küçük, Principal Investigator

✉ melikeunsal463@gmail.com

📞 +90 537 739 62 00

Principal Investigator

Emre Ata, Asst. Prof.

STUDY DIRECTOR

Health Sciences University Sultan 2.Abdülhamid Han Training and Research Hospital

Frequently Asked Questions

Who can join the NCT06851091 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 65 Years, studying Fibromyalgia Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06851091 currently recruiting?

Yes, NCT06851091 is actively recruiting participants. Contact the research team at melikeunsal463@gmail.com for enrollment information.

Where is the NCT06851091 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT06851091 clinical trial?

NCT06851091 is sponsored by Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey. The principal investigator is Emre Ata, Asst. Prof. at Health Sciences University Sultan 2.Abdülhamid Han Training and Research Hospital. The trial plans to enroll 75 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology